Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
PSNL

PSNL - Personalis Inc Stock Price, Fair Value and News

$9.98-0.34 (-3.29%)
Market Closed

11/100

PSNL

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

11/100

PSNL

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$8.14

Target 3M

$9.15

Target 6M

$8.64

PSNL Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

PSNL Price Action

Last 7 days

3.4%

Last 30 days

25.9%

Last 90 days

4.9%

Trailing 12 Months

83.5%

PSNL RSI Chart

PSNL Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

PSNL Valuation

Market Cap

886.3M

Price/Earnings (Trailing)

-12

Price/Sales (Trailing)

12.83

EV/EBITDA

-13.15

Price/Free Cashflow

-13.39

PSNL Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$8.14

Target 3M

$9.15

Target 6M

$8.64

PSNL Fundamentals

PSNL Revenue

Revenue (TTM)

69.1M

Rev. Growth (Yr)

-43.62%

Rev. Growth (Qtr)

-15.74%

PSNL Earnings

Earnings (TTM)

-73.9M

Earnings Growth (Yr)

44.61%

Earnings Growth (Qtr)

-7.96%

PSNL Profitability

Operating Margin

26.67%

EBT Margin

-106.89%

Return on Equity

-43.1%

Return on Assets

-30.42%

Free Cashflow Yield

-7.47%

PSNL Investor Care

Shares Dilution (1Y)

25.70%

Diluted EPS (TTM)

-0.85

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202585.7M80.3M69.1M0
202474.1M80.0M87.5M84.6M
202368.7M67.1M70.5M73.5M
202279.8M76.4M69.0M65.0M
202180.4M82.5M85.0M85.5M
202070.3M74.0M76.6M78.6M
201947.7M54.7M60.2M65.2M
201816.5M23.6M30.7M37.8M
20170009.4M
Get all data in R, Python etc through our Historical Stock Data APIs

About Personalis Inc

PSNL
Personalis, Inc. operates as a cancer genomics company worldwide. The company provides sequencing and data analysis services to support the development of cancer therapies and large-scale genetic research programs. It offers NeXT Platform, which provides data analysis for tumor and its immune microenvironment, from a single limited tissue or plasma sample; ImmunoID Next for tumor profiling from tissue; NeXT Liquid Biopsy for tumor profiling from plasma; NeXT Personal, a liquid biopsy offering for personalized tumor tracking for patients; NeXT Dx Test, a genomic cancer profiling test to optimize therapy selection and match patients to clinical trials; and NeXT SHERPA and NeXT NEOPS for neoantigen prediction capabilities. The company also provides ACE platform for clinical and therapeutic applications, such as neoantigen prediction, biomarker identification, and novel drug target selection. It serves pharmaceutical, biopharmaceutical, diagnostic testing, and biotechnology companies; healthcare providers; universities; non-profits; and government entities. The company was incorporated in 2011 and is headquartered in Fremont, California.
 CEO
 WEBSITEpersonalis.com
 SECTORHealthcare
 INDUSTRYDiagnostics & Research
 EMPLOYEES395

Personalis Inc Frequently Asked Questions

PSNL is the stock ticker symbol of Personalis Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Personalis Inc is 886.27 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check PSNL's fair value in chart for subscribers.

The fair value guage provides a quick view whether PSNL is over valued or under valued. Whether Personalis Inc is cheap or expensive depends on the assumptions which impact Personalis Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PSNL.

As of Wed Jan 28 2026, PSNL's PE ratio (Price to Earnings) is -12 and Price to Sales (PS) ratio is 12.83. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PSNL PE ratio will change depending on the future growth rate expectations of investors.